These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 11234591)

  • 1. [Pharmacologic interventions in primary prevention: lipid lowering drugs, aspirin, antiobesity drugs, and antihypertensive agents].
    Auer J; Berent R; Weber T; Porodko M; Mayr H; Maurer E; Eber B
    Wien Med Wochenschr; 2001; 151(1-2):13-7. PubMed ID: 11234591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prevention of coronary heart disease in the elderly.
    Dornbrook-Lavender KA; Pieper JA; Roth MT
    Ann Pharmacother; 2003 Nov; 37(11):1654-63. PubMed ID: 14565805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacologic prevention of cardiovascular diseases--2005].
    Kancz S
    Orv Hetil; 2005 May; 146(20 Suppl 2):1122-31. PubMed ID: 15945241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V--Statins versus aspirin for primary prevention, and the winner is...?
    Moyad MA; Merrick GS
    Urol Nurs; 2007 Apr; 27(2):166-8. PubMed ID: 17494461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
    Marshall T
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].
    Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F
    Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are at-risk New Zealand women receiving recommended cardiovascular preventive therapy?
    Bupha-Intr O; Rose SB; Lawton BA; Elley CR; Dowell AC
    N Z Med J; 2010 Feb; 123(1309):26-36. PubMed ID: 20186240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethical considerations in cardiovascular prevention.
    Follath F
    Fundam Clin Pharmacol; 2009 Dec; 23(6):669-73. PubMed ID: 19500153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The role of aspirin in the primary prevention of cardiovascular disease].
    Rodondi N; Cornuz J
    Rev Med Suisse; 2006 Mar; 2(56):646-51. PubMed ID: 16597054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of antiplatelet therapy in a diabetic outpatient service of a large urban public hospital.
    Bruno A; Grassi G; Dani F; Degiovanni M; Maghenzani G; Pagano G
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):42-6. PubMed ID: 15871850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease.
    Hennekens CH; Schneider WR
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):95-107. PubMed ID: 18095910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aspirin overprescription in primary cardiovascular prevention.
    Manes C; Giacci L; Sciartilli A; D'Alleva A; De Caterina R
    Thromb Res; 2006; 118(4):471-7. PubMed ID: 16321425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease.
    Blinc A; Poredos P
    Eur J Clin Invest; 2007 Mar; 37(3):157-64. PubMed ID: 17359482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HOPE Study (Heart Outcomes Prevention Evaluation).
    Sleight P
    J Renin Angiotensin Aldosterone Syst; 2000 Mar; 1(1):18-20. PubMed ID: 11967789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
    Waltering A; Hemkens L; Florack C
    Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approaches in the intensive management of cardiovascular risk in the metabolic syndrome.
    Rosenson RS
    Curr Probl Cardiol; 2005 May; 30(5):241-79. PubMed ID: 15829899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.